material proteins. Ultimately, a full understanding of the relationship between spindle pole bodies and other yeast MTOCs and the animal centrosome will require the study of fungi that have retained cilia and thus centrioles [10] , species which have so far not attracted any recent attention.
One notable similarity between rMTOCs and centrosomes is that both link the cell nucleus to the microtubule cytoskeleton. Remarkably, the same players appear in both contexts: thus, SUN domain proteins together with their KASH domain partners (Sad1 and Kms1 in S. pombe) span the nuclear envelope and function in meiotic chromosome movements and nuclear migration in species as diverse as yeast, Dictyostelium, C. elegans, Drosophila and vertebrates [11, 12] . The microtubule minus end-directed motor cytoplasmic dynein and its associated proteins, including LIS1 and NudE (of which Hrs1/Mcp6 is the putative S. pombe ortholog), are other conserved features [13] . While SUN domain proteins face the nucleoplasm and provide a link to chromosomes, KASH domain proteins are exposed to the cytoplasm and connect to various cytoskeletal features, including the centrosome. Finally, cytoplasmic dynein provides the force for centrosome and/or nuclear movement. Disrupting any one of these components is sufficient to disconnect centrosomes from the nucleus, although the centrosome retains microtubule organizing activity (e.g., [14] ). Whether this is also the case for the rMTOC remains to be determined.
With progression through meiosis requiring the timely assembly and disassembly of various microtubule structures (Figure 1) , there is only a narrow window within which rMTOC-mediated formation of a radial microtubule array is needed. This suggests that formation of the rMTOC is tightly regulated. Indeed, Hrs1/Mcp6, the key component of the rMTOC, is specifically expressed during meiotic prophase and is subject to strict downregulation at the transition from meiotic prophase to metaphase of the first meiotic division. Both phosphorylation and degradation of Hrs1/Mcp6 contribute to rMTOC inactivation at the end of meiotic prophase to facilitate reorganization of microtubules into a bipolar spindle [4] . The psychological effects of hallucinogenic, or 'magic' mushrooms were first documented in the medical literature in 1799 [1] : a forty year-old father of four, JS, collected wild mushrooms in London's Green Park and cooked them as a stew for breakfast for himself and his four young children. The apothecary Everard Brande described what happened then: ''Edward, one of the children (eight years old), who had eaten a large proportion of the mushrooms, as they thought them, was attacked with fits of immoderate laughter, nor could the threats of his father or mother refrain him. To this succeeded vertigo, and a great deal of stupor, from which he was roused by being called or shaken, but immediately relapsed.
[.] he sometimes pressed his hands on different parts of his abdomen, as if in pain, but when roused and interrogated as to it, he answered indifferently, yes, or no, as he did to every other question, evidently without any relation to what was asked. About the same time the father, aged forty, was attacked with vertigo, and complained that everything appeared black, then wholly disappeared'' [1] . Such perceptual distortions, mood fluctuation and profoundly altered states of consciousness are now well-documented effects of psilocybin, found in certain species of mushrooms, particularly the genus Psilocybe (Figure 1 ). Like lysergic acid diethylamide (LSD), psilocybin's active metabolite psilocin stimulates serotonin receptors in the brain, most potently the 2A subtype. However, relative to other controlled substances, such as cocaine, amphetamine and heroin, the neurobiological basis of hallucinogenic drug effects is very poorly understood. In particular, very few laboratory studies have investigated their effects on the human brain. Now over 200 years after its first description, the first two studies [2, 3] investigate the effects of psilocybin on the human brain using functional magnetic resonance imaging (fMRI).
The contemporary dearth of research into psychedelic drugs stands in contrast with a largely forgotten literature from an earlier, pre-PubMed time. Before they were outlawed in most countries in the late 1960s due to concerns about abuse liability and psychotic reactions, psilocybin and LSD were not only studied, but also used therapeutically as an adjunct to psychotherapy [4] (for a video on the effects of LSD: http://www. youtube.com/watch? v=V5d4wWGK4Ig). The trials from that era were poorly controlled compared to modern standards, but encouraging preliminary results were reported in various clinical populations, including prisoners, alcoholics and depressed/anxious ('neurotic') patients. However, because the administrative barriers to research involving so-called schedule 1 substances (equivalent to class A substances in the UK) are so high, studies into the effects of psilocybin in humans were largely abandoned from the 1970s onwards.
The two recent studies [2, 3] into the effects of psilocybin on brain responses in humans are thus notable not just for their results, but for the fact that they were performed at all. Both were funded by not-for-profit organisations, including the Multidisciplinary Association for Psychedelic Studies (MAPS), which has been lobbying for renewed research into the potential therapeutic effects of illegal drugs for over 20 years. Among other projects, MAPS also funds an ongoing study into the use of psilocybin to alleviate anxiety in terminally ill cancer patients [5] and methylenedioxymethamphetamine (MDMA, or 'ecstasy') in post-traumatic stress disorder [6] .
The experimental design used in both studies was simple, scanning a group of healthy volunteers on two occasions separated by around two weeks. During one of the scanning sessions, enough intravenous psilocybin was infused to induce clear psychological effects, while on the other only saline was infused. In the first study, the volunteers were asked to simply lie still during scanning with their eyes closed (the so-called 'resting state' in brain imaging terminology). Two types of MRI signals were recorded: blood oxygen level-dependent (BOLD) signals, which are an indirect measure of neuronal activity used in most fMRI studies, and arterial spin labelling (ASL) signals, which measure regional cerebral blood flow over longer periods.
Psilocybin reduced both BOLD signals and cerebral blood flow in several different brain structures, including the anterior and posterior cingulate cortex and thalamus. Functional coupling between the anterior and posterior cingulate (calculated as the scan-to-scan correlation in BOLD signal between the two regions over the fMRI time-series) was also decreased following psilocybin administration. Moreover, across participants, the degree of reduction in cerebral blood flow correlated with the intensity of psychological effects that the participants reported following psilocybin infusion.
Such a relationship with subjective psychological effects is reassuring, as it argues against an interpretation of the changes in BOLD signal simply in terms of blood flow, a common and not unreasonable criticism of many pharmacological fMRI studies. When serotonin was first discovered, it was identified as a potent vasoconstrictor [7] , not a neurotransmitter, and its name even reflects this property ('sero' -blood; 'tonin' -tone). Moreover, its vascular effects are mediated largely via the serotonin 2A receptor, psilocybin's target. Therefore, any changes observed in blood flow measurements following a pharmacological challenge with psilocybin might simply reflect changes in vascular tone as opposed to neuronal activity. The authors clearly anticipated this confound, and added a control condition, measuring BOLD signals while the participants held their breath. Breath holding induces hypercapnia and vasodilatation, and allows the assessment of vascular reactivity on BOLD signals [8] . Importantly, breath hold-induced BOLD responses appeared unchanged following psilocybin infusion, suggesting that their results were not confounded by changes in vascular tone.
Carhart-Harris and colleagues [2] interpret their results in terms of a decrease in activity in critical 'hub' regions of the brain, specifically, the anterior and posterior cingulated cortex, and a loss of coordination between them, caused by the inhibitory effects of serotonin 2A receptor stimulation. This would trigger ''a state of unconstrained cognition''. Consistent with their findings, studies in rats have suggested that cortical local field potentials, which the BOLD signal is believed to reflect, are decreased following serotonin 2A receptor stimulation [9] . However, an earlier study [10] using positron emission tomography reported increased glucose metabolism following psilocybin administration, somewhat clouding the picture.
A second study from the same group [3] focused not on brain activity in the resting state, but studied BOLD signals while participants were cued to recall specific personal memories of positive events from their life. Not only were memories described as more vivid, emotional and positive following psilocybin infusion, but brain responses were enhanced in visual and auditory cortex during autobiographic recollection. These findings led to a somewhat different conclusion than the first study, namely that psilocybin focuses and enhances subjective and neural responses to autobiographical memory rather than resulting in a state of 'unconstrained cognition'. This stark difference between the two sets of experimental findings underscores the difficulty in comparing results from task-related fMRI, as in the second study [3] , in which the effects of an experimental condition are compared with a control condition, with those from relatively unconstrained resting-state fMRI.
On the basis of their results, Carhart-Harris and colleagues [2, 3] suggest that psilocybin may have potential efficacy in the treatment of depression, especially when combined with psychotherapy. This conjecture is based mainly on their observations of a reduction in resting-state cerebral blood flow in the anterior cingulate cortex, which is reliably hyperactive in the depressed state [11] . While a recent study [6] did report slightly lowered depression scores 6 months after psilocybin administration in terminally ill cancer patients, this study specifically excluded individuals with a recent major depressive episode. Therefore, it remains to be seen whether psilocybin might help to treat depression. However, given the administrative obstacles in conducting such a trial under current regulatory frameworks, it is unlikely that we will witness a return to the 1950s heyday of psychedelic psychotherapy any time soon. 1 
